Eupraxia Pharmaceuticals Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 22, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	669	523	161	147	79	35
Market Cap Growth	250.75%	225.34%	9.66%	85.89%	125.87%	-
Enterprise Value	517	441	147	127	58	10
Last Close Price	10.24	10.32	4.51	5.37	3.65	2.45
PB Ratio	3.52	4.74	3.51	124.32	8.08	1.83
P/TBV Ratio	4.44	7.29	65.70	50.06	7.48	1.75
Debt / Equity Ratio	0.02	0.00	0.00	11.71	1.25	0.52
Net Debt / Equity Ratio	-1.00	-1.00	-1.04	-9.96	-1.29	-1.04
Net Debt / EBITDA Ratio	2.91	2.10	1.23	0.32	0.53	1.12
Net Debt / FCF Ratio	4.09	2.76	1.10	0.43	0.63	1.31
Quick Ratio	18.95	14.44	10.74	1.01	6.00	13.38
Current Ratio	19.30	15.12	11.10	1.02	6.08	13.49
Return on Equity (ROE)	-54.52%	-68.76%	-157.31%	-715.19%	-178.04%	-
Return on Assets (ROA)	-33.84%	-39.67%	-61.14%	-88.37%	-52.20%	-68.51%
Return on Capital Employed (ROCE)	-34.30%	-47.70%	-84.80%	-3120.70%	-109.70%	-61.90%
Earnings Yield	-9.80%	-10.12%	-22.84%	-25.44%	-31.75%	-68.66%
FCF Yield	-6.98%	-7.64%	-26.96%	-18.77%	-25.12%	-43.73%
Buyback Yield / Dilution	-26.83%	-17.76%	-40.52%	-25.21%	-55.45%	-102.75%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.